brodalumab

10/01/2023 - "This review provides a summary of the efficacy of brodalumab in plaque psoriasis and difficult-to-treat locations (ie, scalp, nail, palmoplantar), in patients with psoriasis who failed to achieve minimum clearance with other biologics, and it illuminates the most recent pharmacovigilance data obtained from the past 5 years. "
01/01/2023 - "Driven by its lower costs and high response rates, brodalumab was the most cost-effective treatment option for moderate-to-severe plaque psoriasis over a one-year time-horizon within the anti-IL17 class and when compared to all other biologics in France and Germany."
04/01/2020 - "Brodalumab is a highly efficacious and comparably safe therapeutic choice in patients with moderate to severe psoriasis, especially when rapid control of the disease is desired."
02/01/2022 - "Brodalumab was associated with clearance of scalp psoriasis through 12 weeks and improvements in nail psoriasis, including complete nail clearance, through 52 weeks."
01/01/2020 - "Brodalumab is very effective and safe in treating moderate-to severe psoriasis."

06/12/2014 - "Brodalumab significantly improved response rates among patients with psoriatic arthritis. "
01/01/2021 - "Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials."
01/01/2021 - "Brodalumab in the treatment of psoriatic arthritis - the latest reports."
01/01/2016 - "Concerning psoriatic arthritis, at week 12, the numbers (%) of patients fulfilling the American College of Rheumatology response criteria for a 20% improvement were 0 (0%) in the placebo group, and 1 (20%), 2 (40%), and 4 (100%) in the 70mg, 140mg, and 210mg brodalumab groups, respectively. "
06/12/2014 - "We randomly assigned patients with active psoriatic arthritis to receive brodalumab (140 or 280 mg subcutaneously) or placebo on day 1 and at weeks 1, 2, 4, 6, 8, and 10. "

11/01/2016 - "A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease."
12/12/2019 - "Brodalumab failed to affect dysregulated functional gene clusters in Crohn's disease (CD) and systemic juvenile idiopathic arthritis (SJIA), clearly indicating that it may not be effective in the treatment of these diseases. "
11/01/2016 - "To assess the safety and efficacy of brodalumab, a human anti-interleukin-17 receptor monoclonal antibody, in patients with moderate-to-severe Crohn's disease (CD). "
01/01/2021 - "However, secukinumab and brodalumab have shown no clinical benefit in Crohn's disease and led to frequent serious adverse events including worsening of Crohn's disease. "
12/12/2019 - "The repositioning potential for two approved biologics drugs (infliximab and brodalumab) confirmed the drugs' action for approved diseases (ulcerative colitis and Crohn's disease for infliximab and psoriasis for brodalumab). "

05/01/2023 - "In order to evaluate the efficacy of brodalumab, our patients started with mean Psoriasis Area and Severity Index (PASI) values of 12.8 and body surface area (BSA) of 16.9, as well as a Dermatology Life Quality Index (DLQI) of 15.6, highlighting that they reported that the mean baseline visual analog scale (VAS) pruritus was 6.15. "
04/01/2023 - "Brodalumab treatment was associated with improvement in itching and skin pain in Japanese patients with psoriasis. "
04/01/2023 - "Effectiveness of brodalumab in improving itching and skin pain in Japanese patients with psoriasis: The ProLOGUE study."
04/01/2023 - "We assessed the changes in the levels of itching and skin pain after brodalumab treatment in Japanese patients with psoriasis using patient-reported outcomes (PROs). "

01/01/2021 - "Brodalumab demonstrated a significant improvement at week 16 in patients with active axSpA. "
01/01/2021 - "In a multicentre, placebo-controlled phase 3 study (NCT02985983) conducted at 48 sites across Japan, Korea and Taiwan, patients with axSpA were randomised 1:1 to receive subcutaneous brodalumab 210 mg (n=80) or placebo (n=79) at baseline, weeks 1 and 2 and every 2 weeks thereafter, during the 16-week double-blind period. "
01/01/2023 - "Brodalumab demonstrated sustained efficacy and a consistent safety profile in patients with axSpA over 68 weeks. "
01/01/2023 - "Correspondence on 'Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomized, placebo-controlled, phase 3 trial'."
01/01/2023 - "Response to: 'Correspondence on 'Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial'' by Zhao and Huang."